Search results
Showing 201 to 250 of 298 results for breast cancer
Decisions around whether to offer a person surgical treatment should not be based on age and fitness, according to a new report.
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Evidence-based recommendations on lapatinib (Tyverb) and trastuzumab (Herceptin) for treating metastatic hormone receptor-positive breast cancer that overexpresses HER2 in adults.
This quality standard covers the recognition and initial management of ovarian cancer. It describes high-quality care in priority areas for improvement.
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.
Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)
Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment. This involves taking fat from the abdomen or thighs and injecting it into the breast in the area of the deformity caused by surgery.
View recommendations for IPG417Show all sections
Sections for IPG417
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton
This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.
This guideline covers how to assess and monitor body weight and how to prevent someone from becoming overweight or obese before, during and after pregnancy. The aim is to help all women who have a baby to achieve and maintain a healthy weight by adopting a balanced diet and being physically active.
This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
Image-guided radiofrequency excision biopsy of breast lesions (IPG308)
Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.
View recommendations for IPG308Show all sections
Sections for IPG308
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)
Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).
View recommendations for IPG296Show all sections
Sections for IPG296
Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.
View recommendations for IPG268Show all sections
Sections for IPG268
Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)
This appraisal has been updated and replaced by NICE technology appraisal 214.
Laparoscopic mobilisation of the greater omentum for breast reconstruction (IPG253)
Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.
View recommendations for IPG253Show all sections
Sections for IPG253
Gemcitabine for the treatment of metastatic breast cancer (TA116)
Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.
This guideline has been updated and replaced by NICE guideline NG101. This guidance has been updated and replaced by NICE guideline CG164.
Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)
This guideline has been updated and replaced by NICE guideline NG101. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)
This guideline has been updated and replaced by NICE guideline NG101. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)
This guideline has been updated and replaced by NICE guideline NG101. Image-guided vacuum-assisted excision biopsy of benign breast lesions (IPG156)
Evidence-based recommendations on image-guided vacuum-assisted excision biopsy for benign breast lesions. This involves inserting a needle with a suction device through a small opening in the breast to remove non-cancerous lumps.
View recommendations for IPG156Show all sections
Sections for IPG156
Endoscopic axillary lymph node retrieval for breast cancer (IPG147)
Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer. This involves using narrow instruments to remove the lymph nodes through small, rather than large, openings to reduce the risk of infection and other problems.
View recommendations for IPG147Show all sections
Evidence-based recommendations on interstitial laser therapy for breast cancer. This involves using laser energy to destroying the cancer cells.
View recommendations for IPG89Show all sections
Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.
This guidance has been updated and replaced by NICE guideline CG41.
This appraisal has been updated and replaced by NICE guideline CG81.
Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)
This guidance has been updated and replaced by NICE guideline CG81.
This guideline covers how healthcare services for breast cancer should be organised. It aims to improve care for women with breast cancer by recommending which healthcare professionals should be involved in care.
Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)
Evidence-based recommendations on trastuzumab for treating advanced breast cancer in adults.
This guidance has been replaced by NICE guideline CG81.
This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].
This webpage covers NICE guidelines on breast cancer. The table below presents the guidelines alphabetically with links to the...
In development [GID-TA10326] Expected publication date: TBC
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769
Awaiting development [GID-TA11088] Expected publication date: TBC
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Awaiting development [GID-TA10723] Expected publication date: TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
Awaiting development [GID-TA10896] Expected publication date: TBC
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued [GID-TAG411]
Discontinued [GID-TAG390]
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued [GID-TA10066]
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
In development [GID-TA11022] Expected publication date: TBC